Listed

Vanda Pharmaceuticals Inc.

VNDANasdaqCIK 1347178HealthcareFiscal year ends Dec 31

Latest reported revenue, Q3 FY2026$69.8mRevenue, Q3 FY2026, three months to 2026-09-30$69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 29, 2026.

Latest quarter: Q3 FY2026

Three months to Sep 30, 2026, against the same quarter a year earlier.

  • Revenue$69.8mRevenue, Q3 FY2026, three months to 2026-09-30$69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure+24.1% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−33.7%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: −$23.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure+21.9 pts on a year earlier
  • Net margin−32.3%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: −$22.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure+7.8 pts on a year earlier
  • Diluted EPS−$0.37Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure+2.6% on a year earlier
  • Free cash flow−$28.7mFree cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: −$28.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001347178-26-000002. Derived: 9-month figure less the 6-month figure.Capital expenditure: $311.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001347178-26-000002. Derived: 9-month figure less the 6-month figure.Report this figure+9.6% on a year earlier

Last eight quarters

Full statements
Revenue$69.8mOperating margin −33.7%
Diluted EPS−$0.37, Q3 FY2026
Free cash flow−$28.7m, Q3 FY2026
Vanda Pharmaceuticals Inc., key figures for the last eight quarters
Line itemUnitQ4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30Shape over the periods
Revenue$m53.2Revenue, Q4 FY2024, three months to 2024-12-31$53.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure50.0Revenue, Q1 FY2025, three months to 2025-03-31$50.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure52.6Revenue, Q2 FY2025, three months to 2025-06-30$52.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure56.3Revenue, Q3 FY2025, three months to 2025-09-30$56.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure57.2Revenue, Q4 FY2025, three months to 2025-12-31$57.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure51.7Revenue, Q1 FY2026, three months to 2026-03-31$51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure50.5Revenue, Q2 FY2026, three months to 2026-06-30$50.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure69.8Revenue, Q3 FY2026, three months to 2026-09-30$69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(19.3%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Revenue: $53.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure(82.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$41.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Revenue: $50.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(73.2%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$38.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Revenue: $52.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure(55.6%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$31.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $56.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure(70.5%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$40.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Revenue: $57.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure(97.1%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$50.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Revenue: $51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(126.3%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$63.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Revenue: $50.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure(33.7%)Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: −$23.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure
Net margin%(9.2%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Revenue: $53.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure(58.9%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$29.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $50.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(51.7%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$27.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $52.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure(40.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$22.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $56.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure(246.8%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$141.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Revenue: $57.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure(93.9%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$48.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(123.7%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$62.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $50.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure(32.3%)Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: −$22.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Revenue: $69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(0.50)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(0.46)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure(0.38)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figurenot reported (Diluted EPS not reported)(0.82)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(1.04)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053855.Report this figure(0.37)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001347178-26-000002.Report this figure
Free cash flow$m(2.0)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Capital expenditure: $214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure(33.6)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$33.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Capital expenditure: $436.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(15.6)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053855. Derived: 6-month figure less the 3-month figure.Capital expenditure: $299.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053855. Derived: 6-month figure less the 3-month figure.Report this figure(31.8)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$31.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001347178-26-000002. Derived: 9-month figure less the 6-month figure.Capital expenditure: $161.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001347178-26-000002. Derived: 9-month figure less the 6-month figure.Report this figure(29.5)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$29.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Capital expenditure: $102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007460. Derived: 12-month figure less the 9-month figure.Report this figure(50.4)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$50.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Capital expenditure: $221.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031667.Report this figure(31.3)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$31.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053855. Derived: 6-month figure less the 3-month figure.Capital expenditure: $190.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053855. Derived: 6-month figure less the 3-month figure.Report this figure(28.7)Free cash flow, Q3 FY2026, three months to 2026-09-30. operating cash flow − capital expenditureOperating cash flow: −$28.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001347178-26-000002. Derived: 9-month figure less the 6-month figure.Capital expenditure: $311.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001347178-26-000002. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$216.1mOperating margin −70.0%
Diluted EPS−$3.74, FY2025
Free cash flow−$110.4m, FY2025
Vanda Pharmaceuticals Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m269Revenue, FY2021, twelve months to 2021-12-31$268.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-08, accession 0001628280-24-003785.Report this figure254Revenue, FY2022, twelve months to 2022-12-31$254.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-14, accession 0001628280-25-005761.Report this figure193Revenue, FY2023, twelve months to 2023-12-31$192.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure199Revenue, FY2024, twelve months to 2024-12-31$198.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure216Revenue, FY2025, twelve months to 2025-12-31$216.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%15.7%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $42.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-08, accession 0001628280-24-003785.Revenue: $268.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-08, accession 0001628280-24-003785.Report this figure2.5%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-14, accession 0001628280-25-005761.Revenue: $254.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-14, accession 0001628280-25-005761.Report this figure(7.2%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$14.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460.Revenue: $192.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(20.5%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$40.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460.Revenue: $198.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(70.0%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$151.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460.Revenue: $216.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure
Net margin%12.3%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $33.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-08, accession 0001628280-24-003785.Revenue: $268.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-08, accession 0001628280-24-003785.Report this figure2.5%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-14, accession 0001628280-25-005761.Revenue: $254.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-14, accession 0001628280-25-005761.Report this figure1.3%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460.Revenue: $192.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(9.5%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460.Revenue: $198.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(102.0%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$220.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007460.Revenue: $216.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure
Diluted EPS$ per share0.58Diluted EPS, FY2021, twelve months to 2021-12-31$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-08, accession 0001628280-24-003785.Report this figure0.11Diluted EPS, FY2022, twelve months to 2022-12-31$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-14, accession 0001628280-25-005761.Report this figure0.04Diluted EPS, FY2023, twelve months to 2023-12-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(0.33)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(3.74)Diluted EPS, FY2025, twelve months to 2025-12-31−$3.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure
Free cash flow$m63.7Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $64.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-08, accession 0001628280-24-003785.Capital expenditure: $552.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-08, accession 0001628280-24-003785.Report this figure31.3Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $32.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-14, accession 0001628280-25-005761.Capital expenditure: $679.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-14, accession 0001628280-25-005761.Report this figure12.4Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $12.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007460.Capital expenditure: $383.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(16.2)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007460.Capital expenditure: $490.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure(110)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$109.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007460.Capital expenditure: $998.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007460.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Vanda Pharmaceuticals Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$46.8m7,653,737Added+377,749
STATE STREET CORP2026-06-30$21.5m3,516,405Added+500,843
AQR CAPITAL MANAGEMENT LLC2026-06-30$21.4m3,497,695Added+1,894,119
RENAISSANCE TECHNOLOGIES LLC2026-06-30$21.1m3,441,361Reduced−318,198
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$15.4m2,524,040Added+42,549
AIGH Capital Management LLC2026-06-30$12.5m2,044,169Reduced−705,831
DIMENSIONAL FUND ADVISORS LP2026-06-30$10.6m1,727,349Reduced−44,244
MILLENNIUM MANAGEMENT LLC2026-06-30$9.8m1,602,813Reduced−278,188
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$9.1m1,483,787Added+40,822
TWO SIGMA INVESTMENTS, LP2026-06-30$8.3m1,349,072Reduced−49,129

Recent filings

All 1,040 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Vanda Pharmaceuticals Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2908:00 ET10-QQuarterly reportPeriod 2026-09-300001347178-26-000002
2026-10-2816:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-067886
2026-08-0607:39 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-053855
2026-08-0516:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-053308
2026-06-0516:38 ET8-K5.07 Shareholder vote results0001628280-26-041298
2026-05-0707:01 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-031667
2026-05-0616:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-031241
2026-04-2316:48 ETDEF 14AProxy statementPeriod 2026-06-040001628280-26-026893
2026-04-2217:23 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001628280-26-026642
2026-04-0216:30 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-023222

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 12, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures.See the target

About the filer

CIK
1347178
Tickers
VNDA
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:08 ET. Listed shows no prices and gives no investment advice.